New drug ABC008 tested for rare blood cancer
NCT ID NCT05532722
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called ABC008 in 21 adults with T-cell large granular lymphocytic leukemia (T-LGLL), a rare blood cancer. The drug was given as a shot under the skin. The main goal was to check for side effects and see how the drug affects blood counts and other lab values.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABC008
- What this could lead to
- If successful, this could point toward a new treatment option for T-LGLL, a rare leukemia that affects blood cell counts.
- What could go wrong
- This is an early-phase trial with only 21 participants, so results may not apply to all patients. The main focus is safety, not yet effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Southern California
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.